Parse Biosciences is now part of QIAGEN, bringing scalable Evercode single-cell sequencing workflows that enable large studies without specialized instruments. Explore the technology.

TB Management

Transplant

Infectious Disease

Oncology

Sexual & Reproductive Health

Sample Processing

Solutions for Laboratory-Developed Tests

Looking for a quick way to design experiments?
Looking for a quick way to design experiments?
Try the Workflow Configurator. A convenient tool to build experimental workflows and find products to match your needs.
Welcome to My QIAGEN
Dashboard
Account
Orders
Log Out
hero image
Webinar

How to translate complex genomic data

 to clinically-oriented personalized cancer care: a real-world experience

On-demand
icon_0085_cc_gen_calendar-s
Jan 5, 2023
icon_0310_cc_gen_timeinterval-s
30 minutes
Biomedical Research
Cancer (other / various)
Next Generation Sequencing
Cancer Research

Attendees will:

icon_0153_cc_gen_source_okay-s

Explore the challenges of variant classification, including the limitations of manual curation, handling of VUS, and incorporating guideline recommendations.

icon_0153_cc_gen_source_okay-s

Learn how the IORS uses QCI Interpret to evaluate genomic profiles of hereditary cancers and identify variants with clinical utility.

icon_0153_cc_gen_source_okay-s

Receive a demonstration of how QCI Interpret filters and prioritizes variants, transparently computes ACMG/AMP classifications, and auto-generates clinical reports with the latest evidence.

About this webinar

Next-generation sequencing (NGS) tests encompassing multi-gene panels, whole-exome (WES), and whole-genome sequencing (WGS) are becoming an integral part of clinical diagnostics for hereditary cancers. However, analyzing and interpreting these panels can be incredibly time-consuming and complex.

Join Dr. Ana Krivokuca as she presents a use-case of how the Institute for Oncology and Radiology Serbia (IORS), a National Cancer Research Center, uses QCI Interpret, a clinical decision support software, in their NGS testing pipeline to annotate, assess, and interpret the clinical significance of germline variants in hereditary cancers.

Speakers

Ana Krivokuca, PhD, Institute for Oncology and Radiology of Serbia
Dr. Ana Krivokuca is the founder and the Head of the Department for genetic counseling at the Institute for Oncology and Radiology of Serbia. An experienced clinical laboratory geneticist, Dr. Krivokuca specializes in the interpretation of genomic data, variant annotation, and genetic counseling. Currently, her research is focused on genetics and molecular biomarkers in breast and ovarian cancers. She completed her Ph.D. studies in Genetics from the University of Belgrade and her Masters in Bioethics from Clarkson University and Mount Sinai Hospital in New York. To date, Dr. Krivokuca has published over 40 peer-reviewed papers and leads numerous research grants.
Ana Krivokuca, PhD, Institute for Oncology and Radiology of Serbia
Thumbnail Image

Fill out the form to take part in the event

Country and Language
Contact Us
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sample to Insight
© QIAGEN 2013–26. All rights reserved
Trademarks & DisclaimersTerms & ConditionsPrivacyConsent ManagerAccessibilityCancellation and Returns